A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

The funding for 2 million people to receive the twice-yearly preventative treatment lenacapavir is ‘receding in the chaos’ of ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

The PURPOSE trials illuminated the ways in which lenacapavir could be used as a means of pre-exposure prophylaxis effectively, but also featured several adverse events.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...